# EDGAR Filing Document

**Accession Number:** 0001691082
**File Stem:** 0001193125-25-198853
**Filing Date:** 2025-9
**Character Count:** 3377
**Document Hash:** 30f922bb76871b9c29dd728f7a0498da
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-198853.hdr.sgml**: 20260114

**ACCESSION NUMBER**: 0001193125-25-198853

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250909

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LB PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001691082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 917-450-6581

**MAIL ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LB PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20161129

September 9, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Christine Torney

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mary Mast

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Doris Stacey Gama

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Laura Crotty

---

| | |
|:---|:---|
| **Re:** | **LB Pharmaceuticals Inc Registration Statement on Form S-1, as amended (Registration No. 333-289812)**  |

---

Ladies and Gentlemen:

In connection with the above-referenced Registration Statement, as amended, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Act</u>"), we hereby join in the request of LB Pharmaceuticals Inc that the effective date of the Registration Statement, as amended, be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on September 10, 2025, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement.

In connection with the preliminary prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.

Very truly yours,

LEERINK PARTNERS LLC

PIPER SANDLER & CO.

STIFEL, NICOLAUS & COMPANY, INCORPORATED

As Representatives of the several underwriters

[SIGNATURE PAGE FOLLOWS]

------

---

| | |
|:---|:---|
| LEERINK PARTNERS LLC | LEERINK PARTNERS LLC |
| By: | /s/ Rahul Chaudhary |
|  | Name: Rahul Chaudhary |
|  | Title: Senior Managing Director, Head of Equity Capital Markets |
| PIPER SANDLER & CO. | PIPER SANDLER & CO. |
| By: | /s/ Chad Huber |
|  | Name: Chad Huber |
|  | Title: Managing Director |
| STIFEL, NICOLAUS & COMPANY, INCORPORATED | STIFEL, NICOLAUS & COMPANY, INCORPORATED |
| By: | /s/ Ken Clausman |
|  | Name: Ken Clausman |
|  | Title: Managing Director |

---

As representatives of the several underwriters.

*[Signature Page to Acceleration Request Letter]*